The Egyptian Drug Authority (EDA) announced the conclusion of its specialized training program titled “Comprehensive Training on Drug Regulatory Systems and Oversight” (Comprehensive Training on Drug Regulatory Systems and Oversight), attended by a high-level delegation from the Zambian Medicines Regulatory Authority (ZAMRA). The program was part of efforts to enhance regional cooperation and support capacity building for peer regulatory authorities, continuing EDA’s leading regional role in this field.

The program covered all technical and regulatory aspects required by the counterpart authority in Zambia, supporting their efforts to achieve Level 3 maturity (ML3) according to the WHO Global Benchmarking Tool (GBT) issued by the World Health Organization (WHO). This reflects the commitment of both sides to implement best international regulatory standards and practices.

The program included interactive sessions and in-depth technical discussions addressing pharmaceutical product registration systems, good review practices, quality management, pharmacovigilance, risk-based inspections, laboratory oversight, and reliance pathways on reference authorities. These efforts aim to enhance regulatory system efficiency and effectiveness and support the development of risk- and evidence-based regulatory decision-making.

The program also provided a valuable opportunity to exchange experiences and discuss practical challenges in regulatory work, alongside showcasing EDA’s experience in developing an integrated regulatory system based on transparency, continuous improvement, and good governance, thereby strengthening trust in the pharmaceutical system and supporting its sustainability.

The program was attended by several EDA leaders, including Dr. Yasser Ragai, Assistant Chairman for Media Affairs and Supervisor of the Central Administration for Pharmaceutical Care; Dr. Asmaa Fouad, Head of the Central Administration for Biologics, Innovative Products, and Clinical Studies; Dr. Wedian Younis, Head of the Central Administration for Drug Control; and Dr. Dalia Abu Hussein, Director General of the General Administration for Quality Assurance.

This program represents the culmination of fruitful collaboration between both sides and reaffirms EDA’s leading regional role as a hub for regulatory capacity building, supporting regulatory convergence and integration across Africa, enhancing the quality, safety, and efficacy of medical products, and achieving advanced levels of regulatory maturity according to international standards.